{"id":356493,"date":"2023-06-03T01:00:00","date_gmt":"2023-06-02T23:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=356493"},"modified":"2023-04-26T17:00:25","modified_gmt":"2023-04-26T15:00:25","slug":"new-real-world-study-on-tildrakizumab","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/new-real-world-study-on-tildrakizumab\/","title":{"rendered":"New “Real World” Study on Tildrakizumab"},"content":{"rendered":"\n

In a retrospective study of 30 patients with moderate to severe plaque psoriasis, the use of the IL-23 inhibitor tildrakizumab was shown to be effective and safe in clinical practice. Of note, more than half of the patients had psoriasis in hard-to-treat sites. The study population included biologics-naive and biologics-experienced patients. The results were published in the Journal of the European Academy of Dermatology and Venereology<\/em>.<\/strong><\/p>\n\n\n\n

Patients with moderate to severe plaque psoriasis (BSA$<\/sup>) \u226510%, PGA** score \u22653, and PASI#<\/sup> score \u226512) in whom at least two conventional treatment modalities, including systemic therapeutics or phototherapy, had not proven to be effective were included in the study [1,2]. Patients with a PASI score <10 were also included in the study if they had psoriasis lesions in difficult-to-treat locations such as the hands, face, scalp, or genital areas. This classification is consistent with the upgrade criteria of the current S3 guideline [3] .<\/p>\n\n

<\/p>\n\n

\n $<\/em>\n<\/sup> Body surface area involvement<\/em>** Physician Global Assessment<\/em># PASI=Psoriasis Area and Severity Index<\/em><\/p>\n\n

<\/p>\n\n

The study authors point out that nearly half of the patients (46.7%) who had previously been treated with a biologic achieved a comparable response to that seen in biologic-na\u00efve patients [1]. This was evident from the PASI response and multivariate analyses and confirmed results from previous studies [1,4,5].<\/td><\/tr><\/tbody><\/table><\/figure>\n\n

Patients with long-standing psoriasis and concomitant diseases <\/h3>\n\n

The mean age of the study participants was 46.3 \u00b1 13.3 years and the mean disease duration was 14.7 \u00b1 7.3 years. The majority of patients (70%) were men [1]. The included psoriasis patients had no obesity, and the most common comorbidities were hypertension and hypercholesterolemia. More than half of the participants (56.7%) had psoriasis in difficult-to-treat localizations, the most common being nail involvement (23.3%) and scalp involvement (16.7%). In total, 28 of the 30 patients had already undergone at least one treatment attempt with a systemic therapeutic: ciclosporin (n=16), acitretin (n=12), and methotrexate (n=12). 46.7% of patients had been treated at some time in advance with at least one of the following biologics: anti-TNF-\u03b1 (n = 10), anti-IL17, (n = 5), anti-IL23, or anti-IL12\/23 (n = 6). At baseline, all patients tested negative for hepatitis B and C, as well as HIV and tuberculosis. <\/p>\n\n

<\/p>\n\n

\"\"<\/a><\/figure>\n\n

PASI values and other parameters improved strongly during the course <\/h3>\n\n

The dosing regimen usually recommended for tildrakizumab was used: 100 mg tildrakizumab (s.c.) at weeks 0 and 4 and every 12 weeks thereafter [1]. Clinical efficacy was assessed by PASI response at weeks 4, 12, 24, and 36. In addition, PGA, health-related quality of life, and the DLQI&<\/sup> were recorded. During the course of tildrakizumab treatment, the PASI score decreased significantly from 17.6 \u00b1 4.7 at baseline to 4.7 \u00b1 2.5 at week 4 and was 0.5 \u00b1 0.7 at week 36 (Fig. 1).<\/strong> A PASI score \u22643 was achieved by 86.7% of patients at week 12 and by all participants at weeks 24 and 36. PASI 75, 90, and 100 response rates at week 36 were 100%, 96.7%, and 60%, respectively. PGA decreased from 2.8 \u00b1 0.6 at baseline to 1 \u00b1 0.2 at week 4 and was around ~0 in the following weeks. Mean DLQI scores were 13.8 \u00b1 2.9 at baseline and decreased to 3.6 \u00b1 1.6 at week 4 and 0 at week 36, respectively. Patient satisfaction also improved significantly over the course of treatment. <\/p>\n\n

&<\/sup> DLQI=Dermatological Quality of Life Index<\/em><\/p>\n\n

Tildrakizumab (Ilumetri\u00ae<\/sup>) is one of the three interleukin (IL)-23p19 antagonists currently approved in Switzerland for the treatment of plaque psoriasis [6]. <\/p>\n\n

<\/p>\n\n

Literature:<\/p>\n\n

    \n
  1. Gambardella A, et al: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. JDDG 2023; 2(1): 52-58. <\/li>\n\n\n\n
  2. Gisondi P, et al: Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. JEADV 2017; 31(5): 774-790.<\/li>\n\n\n\n
  3. Nast A et al. German S3 guideline for the therapy of psoriasis vulgaris, adapted by EuroGuiDerm – Part 1: Therapy goals and therapy recommendations. JDDG 2021, https:\/\/register.awmf.org,<\/a>(last accessed Mar. 10, 2023). <\/li>\n\n\n\n
  4. Galluzzo M, et al: Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis. J Clin Med 2022; 11(9): 2631.<\/li>\n\n\n\n
  5. Poulin Y, et al: Efficacy of tildrakizumab by patient demographic and disease characteris-tics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis. JEADV 2020; 34(7): 1500-1509.<\/li>\n\n\n\n
  6. Drug Information, www.swissmedicinfo.ch,<\/a>(last accessed Mar. 10, 2023).<\/li>\n<\/ol>\n\n

    <\/p>\n\n

    DERMATOLOGY PRACTICE 2023; 33(2): 30<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    In a retrospective study of 30 patients with moderate to severe plaque psoriasis, the use of the IL-23 inhibitor tildrakizumab was shown to be effective and safe in clinical practice.…<\/p>\n","protected":false},"author":7,"featured_media":306565,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Plaque psoriasis","footnotes":""},"category":[11331,11340,11508,11480,11548,11503],"tags":[12391,67754,67720,67747,67726,67742,67731,12520,14032,17874,67738],"powerkit_post_featured":[],"class_list":["post-356493","post","type-post","status-publish","format-standard","has-post-thumbnail","category-allergology-and-clinical-immunology","category-dermatology-and-venereology","category-education","category-rheumatology","category-rx-en","category-studies","tag-biologics-en","tag-gambardella-et-al-en","tag-il-23-inhibitor-en","tag-ilumetri-en","tag-jeadv-en","tag-journal-of-the-european-academy-of-dermatology-and-venereology-en","tag-localizations","tag-plaque-psoriasis-en","tag-psoriasis-en-2","tag-real-world-en","tag-tildrakizumab-en","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-02 14:18:14","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":356522,"slug":"nouvelle-etude-monde-reel-sur-le-tildrakizumab","post_title":"Nouvelle \u00e9tude \"monde r\u00e9el\" sur le tildrakizumab","href":"https:\/\/medizinonline.com\/fr\/nouvelle-etude-monde-reel-sur-le-tildrakizumab\/"},"it_IT":{"locale":"it_IT","id":356576,"slug":"nuovo-studio-real-world-su-tildrakizumab","post_title":"Nuovo studio \"Real World\" su tildrakizumab","href":"https:\/\/medizinonline.com\/it\/nuovo-studio-real-world-su-tildrakizumab\/"},"pt_PT":{"locale":"pt_PT","id":356464,"slug":"novo-estudo-do-mundo-real-sobre-o-tildrakizumab","post_title":"Novo estudo do \"mundo real\" sobre o tildrakizumab","href":"https:\/\/medizinonline.com\/pt-pt\/novo-estudo-do-mundo-real-sobre-o-tildrakizumab\/"},"es_ES":{"locale":"es_ES","id":356486,"slug":"nuevo-estudio-del-mundo-real-sobre-el-tildrakizumab","post_title":"Nuevo estudio del \"mundo real\" sobre el tildrakizumab","href":"https:\/\/medizinonline.com\/es\/nuevo-estudio-del-mundo-real-sobre-el-tildrakizumab\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/356493","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=356493"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/356493\/revisions"}],"predecessor-version":[{"id":356520,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/356493\/revisions\/356520"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/306565"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=356493"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=356493"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=356493"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=356493"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}